Skip to main content

Table 1 The association between clinicopathological parameters and expression of c-MYC and ß-catenin in 367 CRC patients (cohort1)

From: Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ß-catenin

  Total c-Myc IHC P-Value c-Myc RNA ISH (score) P-Value ß-catenin IHC (%) P-Value
Negative Positive Negative Positive Negative Positive
Age
 mean 64.2 64.6 63.9 0.537 63.4 64.7 0.334 64.1 63.7 0.257
Sex
 male 205 89 (43.4 %) 116 (56.6 %) 0.431 72 (35.1 %) 133 (64.9 %) 0.720 82 (40.0 %) 123 (60.0 %) 0.924
 female 162 77 (47.5 %) 85 (52.5 %)   54 (33.3 %) 108 (66.7 %)   64 (39.5 %) 98 (60.5 %)  
Location
 cecum 13 12 (92.3 %) 1 (7.7 %) 0.002 12 (92.3 %) 1 (7.7 %) 0.039 11 (84.6 %) 2 (15.4 %) 0.103
 ascending colon 55 39 (70.9 %) 16 (29.1 %)   37 (67.3 %) 18 (32.7 %)   36 (65.5 %) 19 (34.5 %)  
 hepatic flexure 22 14 (63.6 %) 8 (36.4 %)   17 (77.3 %) 5 (22.7 %)   14 (63.6 %) 8 (36.4 %)  
 transverse colon 16 10 (62.5 %) 6 (37.5 %)   11 (68.8 %) 5 (31.3 %)   11 (68.8 %) 5 (31.3 %)  
 splenic flexure 6 5 (83.3 %) 1 (16.7 %)   4 (66.7 %) 2 (33.3 %)   4 (66.7 %) 2 (33.3 %)  
 descending colon 18 15 (83.3 %) 3 (16.7 %)   15 (83.3 %) 3 (16.7 %)   13 (72.2 %) 5 (27.8 %)  
 sigmoid colon 114 53 (46.5 %) 61 (53.5 %)   64 (56.1 %) 50 (43.9 %)   62 (54.4 %) 52 (45.6 %)  
 rectum 123 71 (57.7 %) 52 (42.3 %)   89 (72.4 %) 34 (27.6 %)   61 (49.6 %) 62 (50.4 %)  
pT stage
 0–2 58 14 (24.1 %) 44 (75.9 %) <0.001 14 (24.1 %) 44 (75.9 %) 0.075 17 (29.3 %) 41 (70.7 %) 0.076
 3–4 309 152 (49.2 %) 157 (50.8 %)   112 (36.2 %) 197 (63.8 %)   129 (41.7 %) 180 (58.3 %)  
Differentiation
 LG 331 142 (42.9 %) 189 (57.1 %) 0.007 101 (30.5 %) 230 (69.5 %) <0.001 124 (37.5 %) 207 (62.5 %) 0.006
 HG 36 24 (66.7 %) 12 (33.3 %)   25 (69.4 %) 11 (30.6 %)   22 (61.1 %) 14 (38.9 %)  
LN metastasis
 absent 168 67 (39.9 %) 101 (60.1 %) 0.058 58 (34.5 %) 110 (65.5 %) 0.943 63 (37.5 %) 105 (62.5 %) 0.412
 present 199 99 (49.7 %) 100 (50.3 %)   68 (34.2 %) 131 (65.8 %)   83 (41.7 %) 116 (58.3 %)  
Lymphatic invasion
 absent 158 63 (39.9 %) 95 (60.1 %) 0.073 51 (32.3 %) 107 (67.7 %) 0.471 61 (38.6 %) 97 (61.4 %) 0.689
 present 209 103 (49.3 %) 106 (50.7 %)   75 (35.9 %) 134 (64.1 %)   85 (40.7 %) 124 (59.3 %)  
Perineural invasion
 absent 154 49 (31.8 %) 105 (68.2 %) 0.025 78 (30.7 %) 176 (69.3 %) 0.028 99 (39.0 %) 155 (61.0 %) 0.636
 present 113 61 (54.0 %) 52 (46.0 %)   48 (42.5 %) 65 (57.5 %)   47 (41.6 %) 66 (58.4 %)  
Venous invasion
 absent 296 133 (44.9 %) 163 (55.1 %) 0.814 101 (34.1 %) 195 (65.9 %) 0.862 121 (40.9 %) 175 (59.1 %) 0.381
 present 71 33 (46.5 %) 38 (53.5 %)   25 (35.2 %) 46 (64.8 %)   25 (35.2 %) 46 (64.8 %)  
Tumor border
 expanding 60 25 (41.7 %) 35 (58.3 %) 0.544 27 (45.0 %) 33 (55.0 %) 0.057 24 (40.0 %) 36 (60.0 %) 0.970
 infiltrative 307 141 (45.9) 166 (54.1 %)   99 (32.2 %) 208 (67.8 %)   122 (39.7 %) 185 (60.3 %)  
Size (cm)
 mean 5.3 5.8 4.8 <0.001 6.0 4.9 <0.001 5.6 5.0 0.007
Distant metastasis
 absent 299 131 (43.8 %) 168 (56.2 %) 0.252 97 (32.4 %) 202 (67.6 %) 0.110 115 (38.5 %) 184 (61.5 %) 0.278
 present 68 35 (51.5 %) 33 (48.5 %)   29 (42.6 %) 39 (57.4 %)   31 (45.6 %) 37 (54.4 %)  
pTNM stage
 I, II 162 64 (39.5 %) 98 (60.5 %) 0.050 55 (34.0 %) 107 (66.0 %) 0.891 59 (37.1 %) 100 (62.9 %) 0.399
 III, IV 205 102 (49.8 %) 103 (50.2 %)   71 (34.6 %) 134 (65.4 %)   85 (41.5 %) 120 (58.5 %)  
MSI status
 MSS/MSI-L 323 141 (43.7 %) 182 (56.3 %) 0.490 105 (32.5 %) 218 (67.5 %) 0.019 177 (54.8 %) 146 (45.2 %) <0.001
 MSI-H 32 16 (50.0 %) 16 (50.0 %)   17 (53.1 %) 15 (46.9 %)   28 (87.5 %) 4 (12.5 %)  
Chemotherapy status
 none 97 41 (42.3 %) 56 (57.7 %) <0.001 67 (69.1 %) 30 (30.9 %) 0.748 49 (50.5 %) 48 (49.5 %) 0.175
 pre- 0 0 (0.0 %) 0 (0.0 %)   0 (0.0 %) 0 (0.0 %)   0 (0.0 %) 0 (0.0 %)  
 post- 269 177 (65.8 %) 92 (34.2 %)   181 (67.3 %) 88 (32.7 %)   162 (60.2 %) 107 (39.8 %)  
 Pre- and post- 1 1 (100.0 %) 0 (0.0 %)   1 (100.0 %) 0 (0.0 %)   1 (100.0 %) 0 (0.0 %)  
  1. P-values are calculated by using χ2-test or Fisher’s exact test
  2. Abbreviations: CRC colorectal cancer, T tumor, LG low grade, HG high grade, LN lymph node, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, IHC immunohistochemistry, ISH in-situ hybridization